Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 (CONTENT1)

Investigator: Rose Khavari, MD

Study Coordinator: Rashmi Pande

Status: Enrolling

ClinicalTrials.gov Number: N/A

Phone: 716.289.6679

Protocol Number: Pro00015517


The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS). Condition - Urinary Incontinence, Overactive Bladder Intervention - Drug: AbobotulinumtoxinA, Drug: AbobotulinumtoxinA Placebo Phase - Phase 3 ClinicalTrials.gov Identifier: NCT02660138
More to Explore